Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

4

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Bacterial penicillin-binding protein

4

D-alanyl-D-alanine carboxypeptidase

4

Solute carrier family 22 member 7

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1964

4

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Bone and joint infections

4

Endocarditis

4

Respiratory tract infections

4

Septicaemia

4

Skin and soft tissue infections

4

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Curative

4

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

4

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Eli Lilly

4

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

4

FDA UNII

4

PUBCHEM

3

CHEBI

2

ChEMBL

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

OTHER BETA-LACTAM ANTIBACTERIALS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

First-generation cephalosporins

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

3

Principal Form

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 4 of 4 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

CEPHALOTHIN

R72LW146E6

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1964

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

D-alanyl-D-alanine carboxypeptidase

Solute carrier family 22 member 7

Conditions:

Respiratory tract infections

Urogenital infections

Bone and joint infections

Skin and soft tissue infections

Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram po...

sitive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides.

CEPHALOTHIN HEMI(TRANS-1,4-BIS(AMINOMETHYL)CYCLOHEXANE)

2QFS1UDW47

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1964

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

D-alanyl-D-alanine carboxypeptidase

Solute carrier family 22 member 7

Conditions:

Respiratory tract infections

Urogenital infections

Bone and joint infections

Skin and soft tissue infections

Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram po...

sitive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides.

CEPHALOTHIN SODIUM

C22G6EYP8B

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1964

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Bacterial penicillin-binding protein

D-alanyl-D-alanine carboxypeptidase

Solute carrier family 22 member 7

Conditions:

Respiratory tract infections

Urogenital infections

Bone and joint infections

Skin and soft tissue infections

Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram po...

sitive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides.

CEPHALOTHIN ETHANOLAMINE

IW6KLJ5ANA

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1964

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Bacterial penicillin-binding protein

D-alanyl-D-alanine carboxypeptidase

Solute carrier family 22 member 7

Conditions:

Respiratory tract infections

Urogenital infections

Bone and joint infections

Skin and soft tissue infections

Cephalothin is a first generation, semisynthetic analogue of natural cephalosporin antibiotic. The in-vitro bactericidal action of Cephalothin results from inhibition of cell-wall synthesis. In general, Cephalothin has higher activity against Gram po...

sitive than Gram negative organisms. Cephalothin is primarily indicated in conditions like bone and joint infection, genitourinary tract infections, respiratory tract infections, soft tissue and skin infections and others. The severe or irreversible adverse effects of Cephalothin, which give rise to further complications, include nephrotoxicity, hemolytic anemia. Cephalothin produces potentially life-threatening effects, which include anaphylaxis, serum sickness syndrome. The symptomatic adverse reactions produced by Cephalothin are: rashes, urticaria, allergic reactions, thrombophlebitis, pain at injection site. Co-administration of diuretics, such as furanthril, ethacrynic acid and nephrotoxic antibiotics may increase the risk of renal damage. Reciprocal inactivation could be observed during in vitro mixing of Cephalothin with aminoglycosides.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1